EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries

Objective To determine whether the 2003 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been followed in general practice. Design Cross-sectional survey. Methods The EUROASPIRE survey was carried out in 2006–2007 in 66 general practices in 12 European countries. Patients without a history of coronary or other atherosclerotic disease either started on antihypertensive and/or lipid-lowering and/or antidiabetes treatments were identified retrospectively, interviewed and examined at least 6 months after the start of medication. Results Four thousand, three hundred and sixty-six high-risk individuals (57.7% females) were interviewed (participation rate 76.7%). Overall, 16.9% smoked cigarettes, 43.5% had body mass index ≥ 30 kg/m2, 70.8% had blood pressure ≥ 140/90 mmHg (≥ 130/80 in people with diabetes mellitus), 66.4% had total cholesterol ≥ 5.0 mmol/l (≥ 4.5 mmol/l in people with diabetes) and 30.2% reported a history of diabetes. The risk factor control was very poor, with only 26.3% of patients using antihypertensive medication achieving the blood pressure goal, 30.6% of patients on lipid-lowering medication achieving the total cholesterol goal and 39.9% of patients with self-reported diabetes having haemoglobin A1c ≤ 6.1%. The use of blood pressure-lowering medication in people with hypertension was: β-blockers 34.1 % angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers 60.8%, calcium channel blockers 26.3% diuretics 36.9% Statins were prescribed in 47.0% of people with hypercholesterolemia. About 22.0% of all patients were on aspirin or other antiplatelet medication. Conclusion The EUROASPIRE III survey in general practice shows that the lifestyle of people being treated as high cardiovascular risk is a major cause of concern with persistent smoking and high prevalence of both obesity and central obesity. Blood pressure, lipid and glucose control are completely inadequate with most patients not achieving the targets defined in the prevention guidelines. Primary prevention needs a systematic, comprehensive, multidisciplinary approach, which addresses lifestyle and risk factor management by general practitioners, nurses and other allied health professionals, and a health care system which invests in prevention.

[1]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[2]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.

[3]  S. Ebrahim,et al.  Multiple risk factor interventions for primary prevention of coronary heart disease. , 2011, The Cochrane database of systematic reviews.

[4]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[5]  M. Law,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[6]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[7]  Rosanna Abbate,et al.  Adherence to Mediterranean diet and health status: meta-analysis , 2008, BMJ : British Medical Journal.

[8]  G. Remuzzi,et al.  β-cell transplantation for diabetes therapy – Authors' reply , 2008, The Lancet.

[9]  O. Faergeman,et al.  Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial , 2008, The Lancet.

[10]  Catherine M Champagne,et al.  The evidence for dietary prevention and treatment of cardiovascular disease. , 2008, Journal of the American Dietetic Association.

[11]  Cholesterol Treatment Trialists' Collaborators Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.

[12]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[13]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) , 2007 .

[14]  E. Vartiainen,et al.  Serum cholesterol during 27 years: assessment of systematic error and affecting factors and their role in interpreting population trends. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[15]  Kumanan Wilson,et al.  Effectiveness of smoking cessation therapies: a systematic review and meta-analysis , 2006, BMC public health.

[16]  P. Amouyel,et al.  Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. , 2006, The Journal of nutrition.

[17]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[18]  Karina W Davidson,et al.  Assessment of the white-coat effect , 2006, Journal of hypertension.

[19]  U. Keil,et al.  Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[20]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[21]  J. Manson,et al.  Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. , 2005, Journal of applied physiology.

[22]  Stephen W. Gutkin,et al.  Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study , 2005, Current medical research and opinion.

[23]  David B Allison,et al.  Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. , 2004, Circulation.

[24]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). , 2004, Archives des maladies du coeur et des vaisseaux.

[25]  N. Poulter,et al.  Hypertension management and control among English adults aged 65 years and older in 2000 and 2001 , 2004, Journal of hypertension.

[26]  R. Cooper,et al.  Hypertension Treatment and Control in Five European Countries, Canada, and the United States , 2004, Hypertension.

[27]  A. Haider,et al.  Management of dyslipidemia in primary care. , 2003, The Canadian journal of cardiology.

[28]  F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[29]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[30]  Ihab Hajjar,et al.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. , 2003, JAMA.

[31]  A. Rudnicka,et al.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[32]  L. Erhardt,et al.  Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. , 2002, Family practice.

[33]  D. Kromhout,et al.  Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. , 2002, Circulation.

[34]  S. Oparil,et al.  Effects of ACE Inhibitors, Calcium Antagonists, and Other Blood Pressure lowering Drugs , 2001, Current hypertension reports.

[35]  J. Neoptolemos,et al.  Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study , 2000, The Lancet.

[36]  A. Morice,et al.  Breath carbon monoxide as an indication of smoking habit. , 2000, Chest.

[37]  K. Fagerström,et al.  Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. , 2000, European heart journal.

[38]  R. West,et al.  Smoking cessation: evidence based recommendations for the healthcare system , 1999, BMJ.

[39]  Ian Graham,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.

[40]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[41]  C. Bulpitt,et al.  The Hypertension in the Very Elderly Trial (HYVET) , 1994, Drugs & aging.

[42]  N J Wald,et al.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.

[43]  Stanley Lemeshow,et al.  Adequacy of Sample Size in Health Studies. , 1991 .

[44]  M. Kornitzer,et al.  BELGIAN HEART DISEASE PREVENTION PROJECT: INCIDENCE AND MORTALITY RESULTS , 1983, The Lancet.

[45]  I. Holme,et al.  EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE Report from the Oslo Study Group of a Randomised Trial in Healthy Men , 1981, The Lancet.

[46]  G. Moneta Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004 , 2009 .

[47]  F. Ovalle 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .

[48]  W. Elliott Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials , 2009 .

[49]  S. Allender,et al.  European cardiovascular disease statistics , 2008 .

[50]  Ž. Reiner,et al.  Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service. , 2005, Croatian medical journal.

[51]  L. Stead,et al.  Physician advice for smoking cessation. , 2004, The Cochrane database of systematic reviews.

[52]  F. Palace,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001 .

[53]  David R. Wood,et al.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.

[54]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .